Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ± lenalidomide as first-line therapy in patients with DLBCL. From December 2019 to August 2020, 83 adults with untreated DLBCL (International Prognostic Index 2-5) were screened and 66 were randomly assigned (33 per arm) to R-CHOP-tafasitamab (arm T) or R-CHOP-tafasitamab-lenalidomide (arm T/L) for 6 cycles. Primary end point was safety; secondary end points included end-of-treatment (EoT) overall response rate (ORR) and complete response (CR) rate. All patients had ≥1 treatment-emergent adverse event, mostly grade 1 or 2. Grade ≥3 neutropenia and thrombocytopenia occurred, respectively, in 57.6% and 12.1% (arm T) and 84.8% and 36.4% (arm T/L) of patients. Nonhematologic toxicities occurred at similar rates among arms. R-CHOP mean relative dose intensity was ≥89% in both arms. EoT ORR was 75.8% (CR 72.7%) in arm T and 81.8% (CR 66.7%) in arm T/L; best ORR across visits was 90.0% and 93.9%. Eighteen-month duration of response and of CR rates were 72.7% and 74.5% (arm T) and 78.7% and 86.5% (arm T/L); 24-month progression-free and overall survival rates were 72.7% and 90.3% (arm T) and 76.8% and 93.8% (arm T/L). Manageable safety and promising signals of efficacy were observed in both arms. Potential benefit of adding tafasitamab + lenalidomide to R-CHOP is being investigated in phase 3 frontMIND (NCT04824092). This study is registered at www.clinicaltrials.gov as #NCT04134936.

4th Department of Internal Medicine Hematology Charles University Hospital and Faculty of Medicine Hradec Králové Czech Republic

Bioaraba Vitoria Gasteiz Spain

Charles University General Hospital Prague Czech Republic

Department of Hematology Hospital San Pedro de Alcantara Cáceres Spain

Department of Hematology Osakidetza Basque Health Service Araba University Hospital Vitoria Gasteiz Spain

Department of Hematology Université Catholique de Louvain CHU UCL Namur Yvoir Belgium

Department of Internal Medicine University Hospital of St Pölten St Pölten Austria

Department of Oncology of the 2nd Faculty of Medicine of Charles University and University Hospital in Motol Prague Czech Republic

Division of Hematology and Hemostaseology Department of Medicine 1 Medical University of Vienna Vienna Austria

Division of Hematology Mayo Clinic Rochester MN

Karl Landsteiner University of Health Sciences Karl Landsteiner Institute for Nephrology and Hemato Oncology St Pölten Austria

Medizinische Klinik und Poliklinik 2 Universitätsklinik Würzburg Würzburg Germany

MorphoSys AG Planegg Germany

MorphoSys US Inc Boston MA

Norton Cancer Institute St Matthews Campus Louisville KY

US Oncology Research and Rocky Mountain Cancer Centers Aurora CO

000      

00000naa a2200000 a 4500

001      

bmc24001023

003      

CZ-PrNML

005      

20240213093551.0

007      

ta

008      

240109s2023 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1182/blood.2023020637 $2 doi

035    __

$a (PubMed)37369099

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Belada, David $u 4th Department of Internal Medicine-Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic $1 https://orcid.org/0000000249816188 $7 mzk2006322730

245    10

$a Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study / $c D. Belada, K. Kopeckova, JM. Bergua Burgues, D. Stevens, M. André, EP. Persona, P. Pichler, PB. Staber, M. Trneny, J. Duell, M. Waldron-Lynch, S. Wagner, A. Mukhopadhyay, M. Dirnberger-Hertweck, JM. Burke, GS. Nowakowski

520    9_

$a Anti-CD19 immunotherapy tafasitamab is used in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant. Open-label, phase 1b, First-MIND study assessed safety and preliminary efficacy of tafasitamab + R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) ± lenalidomide as first-line therapy in patients with DLBCL. From December 2019 to August 2020, 83 adults with untreated DLBCL (International Prognostic Index 2-5) were screened and 66 were randomly assigned (33 per arm) to R-CHOP-tafasitamab (arm T) or R-CHOP-tafasitamab-lenalidomide (arm T/L) for 6 cycles. Primary end point was safety; secondary end points included end-of-treatment (EoT) overall response rate (ORR) and complete response (CR) rate. All patients had ≥1 treatment-emergent adverse event, mostly grade 1 or 2. Grade ≥3 neutropenia and thrombocytopenia occurred, respectively, in 57.6% and 12.1% (arm T) and 84.8% and 36.4% (arm T/L) of patients. Nonhematologic toxicities occurred at similar rates among arms. R-CHOP mean relative dose intensity was ≥89% in both arms. EoT ORR was 75.8% (CR 72.7%) in arm T and 81.8% (CR 66.7%) in arm T/L; best ORR across visits was 90.0% and 93.9%. Eighteen-month duration of response and of CR rates were 72.7% and 74.5% (arm T) and 78.7% and 86.5% (arm T/L); 24-month progression-free and overall survival rates were 72.7% and 90.3% (arm T) and 76.8% and 93.8% (arm T/L). Manageable safety and promising signals of efficacy were observed in both arms. Potential benefit of adding tafasitamab + lenalidomide to R-CHOP is being investigated in phase 3 frontMIND (NCT04824092). This study is registered at www.clinicaltrials.gov as #NCT04134936.

650    _2

$a dospělí $7 D000328

650    _2

$a lidé $7 D006801

650    _2

$a lenalidomid $x terapeutické užití $7 D000077269

650    _2

$a myší monoklonální protilátky $x škodlivé účinky $7 D058846

650    _2

$a rituximab $x škodlivé účinky $7 D000069283

650    12

$a difúzní velkobuněčný B-lymfom $x patologie $7 D016403

650    _2

$a vinkristin $x škodlivé účinky $7 D014750

650    _2

$a cyklofosfamid $x škodlivé účinky $7 D003520

650    _2

$a prednison $x škodlivé účinky $7 D011241

650    _2

$a doxorubicin $x škodlivé účinky $7 D004317

650    _2

$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971

655    _2

$a randomizované kontrolované studie $7 D016449

655    _2

$a klinické zkoušky, fáze I $7 D017426

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Kopeckova, Katerina $u Department of Oncology of the 2nd Faculty of Medicine of Charles University and University Hospital in Motol, Prague, Czech Republic $1 https://orcid.org/000000021907163X

700    1_

$a Bergua Burgues, Juan Miguel $u Department of Hematology, Hospital San Pedro de Alcantara, Cáceres, Spain $1 https://orcid.org/0000000182291208

700    1_

$a Stevens, Don $u Norton Cancer Institute-St. Matthews Campus, Louisville, KY

700    1_

$a André, Marc $u Department of Hematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium $1 https://orcid.org/000000017101810X

700    1_

$a Persona, Ernesto Perez $u Bioaraba (Onco-hematology Research Group), Vitoria-Gasteiz, Spain $u Department of Hematology, Osakidetza Basque Health Service, Araba University Hospital, Vitoria-Gasteiz, Spain

700    1_

$a Pichler, Petra $u Department of Internal Medicine, University Hospital of St. Pölten, St. Pölten, Austria $u Karl Landsteiner University of Health Sciences, Karl Landsteiner Institute for Nephrology and Hemato Oncology, St. Pölten, Austria

700    1_

$a Staber, Philipp B $u Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000167297708

700    1_

$a Trneny, Marek $u Charles University General Hospital, Prague, Czech Republic $1 https://orcid.org/0000000269526073 $7 nlk20000083659

700    1_

$a Duell, Johannes $u Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg, Germany

700    1_

$a Waldron-Lynch, Maeve $u MorphoSys US Inc, Boston, MA

700    1_

$a Wagner, Steve $u MorphoSys AG, Planegg, Germany

700    1_

$a Mukhopadhyay, Amitava $u MorphoSys AG, Planegg, Germany $1 https://orcid.org/0000000278970889

700    1_

$a Dirnberger-Hertweck, Maren $u MorphoSys AG, Planegg, Germany

700    1_

$a Burke, John M $u US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO $1 https://orcid.org/0000000251446710

700    1_

$a Nowakowski, Grzegorz S $u Division of Hematology, Mayo Clinic, Rochester, MN

773    0_

$w MED00000807 $t Blood $x 1528-0020 $g Roč. 142, č. 16 (2023), s. 1348-1358

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37369099 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240109 $b ABA008

991    __

$a 20240213093548 $b ABA008

999    __

$a ok $b bmc $g 2049568 $s 1210717

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 142 $c 16 $d 1348-1358 $e 2023Oct19 $i 1528-0020 $m Blood $n Blood $x MED00000807

LZP    __

$a Pubmed-20240109